PubMed Health⌕ Search

Biomedical subjects

M Schlienger

Publications and source records attributed to M Schlienger.

At least 91 records · Page 5Linked to original sources
PubMed1990

[Cloacogenic cancers of the anal canal: a retrospective study of 17 cases].

This study involved 17 cloacogenic cancers classified on the Morson and Jass histological scale and on the TNM clinical classification as T1 (4), T2 (3), T3 (3) and T4 (7) and including 5 N+ cases at the time of diagnosis. Treatment combined radiotherapy and surgery and the overall actuarial survival was 45% after 5 years. These results confirm that the response to treatment of cloacogenic cancers is similar to that of epidermoid cancers, notably with regard to the response to radiotherapy, and that the prognosis depends above all on the initial extent of the cancer. In contrast, cancers showing little or no differentiation (small cell cloacogenic cancers) are distinguished from other duct cancers by their explosive metastatic potential.

Adult↗
PubMed1989

[Peroperative radiotherapy in tumors of the pancreas].

Intraoperative irradiation has been devised as a method to safely deliver higher radiation doses to the tumors while minimizing the dose to the surrounding normal tissues. Among 14 patients treated by intraoperative radiotherapy in our institution, 8 had a pancreatic carcinoma (unresected in 7 patients, and partially resected in 1 patient). Anesthetized patients were transferred with the incision temporarily closed from the fourth floor operative room to the basement accelerator suite. A single dose of 15 to 20 Gy with 20meV electrons was delivered. Five patients with a carcinoma of the head of the pancreas had had a biliary and a digestive by-pass. After surgery all the patients received an additional 40 Gy and chemotherapy with 5-Fluorouracil. There was nor post-operative mortality neither morbidity. Four patients with preoperative pain had no pain after treatment. Five patients died after 5 to 10 months and two patients are alive with a follow-up of 4 and 9 months. Because of the short follow-up and the small number of patients no conclusion on survival may be made. Nevertheless, in other experiences good palliation has been generally obtained. Significant difference in survival time was noticed in a Japanese experience in unresected cases. In 16 patients with resected carcinomas a 41% survival rate at 2 years has been observed in a North American experience. Thus we are encouraged to continue this approach.

Aged↗
PubMed1989

Gallbladder carcinoma: role of radiation therapy.

Gallbladder carcinoma continues to be a discouraging disease. Prognosis after resection still remains poor. Radiation therapy has been used in an attempt to improve the prognosis but only a few series of less than ten cases have been reported. Since 1977 we have treated 20 patients with gallbladder carcinoma with postoperative radiotherapy (mean total dose 4200 radiation absorbed dose). In four patients all the tumour was resected with the intent of cure. In 12 patients, the lesion was partially resected and in four patients no resection was performed. Seven patients in whom the tumour was partially resected or not resected also had chemotherapy. Our evaluation was retrospective and we compared our results with historical control groups comparable with respect to surgical procedures and pathological staging. In patients operated on for cure, one patient is alive at 84 months, the others died at 7, 8 and 33 months. In patients in whom the tumour was partially resected the mean survival time was 8.1 months and two patients are still alive 7.0 months after treatment. According to the Nevin classification the mean survival time in stage IV and V patients was respectively 9.2 and 7.2 months. There was no difference in survival between patients treated or not treated with chemotherapy. This experience is the largest published and suggests that radiotherapy may increase survival after no resection or palliative resection of gallbladder carcinoma.

Adenocarcinoma↗
PubMed1989

Epidermoid carcinoma of the anal canal treatment results and prognostic variables in a series of 242 cases.

UNLABELLED: From 1972 to 1985, 260 cases of anal canal epidermoid carcinoma were irradiated. Eighteen cases treated for palliation were excluded from the study; 242 (93%) were treated with curative intent. The sex ratio was 1/5.5; mean age was 66 years. HISTOLOGY: 60.3% were well differentiated epidermoid carcinoma; 31.0% moderately differentiated and 8.7%, cloacogenic cases. Staging: T1: 11.5%; T2: 16.1%; T3a: 17%; T3b: 33.5%; and T4: 21.9%. Abnormal inguinal nodes were present in 15.3% of cases. Crude overall survival (Kaplan-Meier) for the 242 cases is 86.4% at 1 year, 63.9% at 3 years, 51.2% at 5 years, and 30.8% at 10 years. Radiation therapy was the sole treatment for 193 cases. No chemotherapy was given. Patients were irradiated by external beam. They received a first course of X rays (mostly 18 MV, some 6 MV) 40 to 45 Gy (box technique) over 4 to 5 weeks in the pelvis. Age and size of tumor were considered when deciding on the target volume. After a rest period of 4 to 6 weeks, a second course of 15 to 20 Gy in 2 weeks was given through a perineal field by electron-beam of suitable energy. The mean total dose was 60.56 Gy and median was 62.5 Gy; the mean overall treatment duration was 85.3 days (median 82 days) and the mean Time Dose Factor including decay factor was 98.96. In this group, 5-year determinate survival was: T1-T2, 84.5%; T3a, 74.8%; T3b, 64.9%; T4, 58.9%. In 147/193 patients (76.2%) local control was achieved. The overall anal conservation rate was 62.6%. In 106 cases (55%), the anus had maintained normal function. The 5-year survival rate by N was 73.3% in the absence of inguinal nodes (169 cases) and 36.1% if such nodes were present. There was no significant difference in survival rate according to histological type. In the second group, receiving radiation therapy plus surgery, 33/49 cases (T3b-T4) were irradiated before surgery (median dose 40.5 Gy). Post operative radiation therapy was administered in 16 cases (T3b-T4) (median dose 49.6 Gy). The 5-year determinate survival is 53.2% for T3b and 79% for T4. According to the log-rank test, there was no significant difference between survival with radiation therapy alone and radiation therapy plus surgery. Multivariate analysis of the whole group indicated that T stage is the only predictive variable.(ABSTRACT TRUNCATED AT 400 WORDS)

Adult↗
PubMed1989

Fast neutron boost for the treatment of grade IV astrocytomas.

A previous study, on grade IV astrocytomas, compared a combination of photons and fast neutron boost to photons only, both treatments being delivered following a concentrated irradiation schedule. A slight improvement in survival was observed after neutron boost for non operated patients, but not for operated patients. Since death was always related to local recurrence and since no complication occurred after neutron boost, the neutron dose was increased from 6 to 7 Gy in January 1985. No improvement in survival was observed for patients treated with neutron boost after complete resection. After subtotal resection, the group that was treated with the higher neutron boost (7 Gy) showed a significant benefit in survival at twelve months. When patients had only a biopsy before irradiation, there was a benefit in survival after neutron boost, but no additional benefit was gained when the size of the neutron boost was increased from 6 to 7 Gy.

Brain Neoplasms↗
PubMed1989

[Stereoradiotherapy of small brain lesions].

Stereoradiotherapy is the stereotaxy guided high-dose irradiation of small (less than 3 cm) intracerebral lesions. Its aim is to induce necrosis or sclerosis inside the target volume. Several techniques permit us to obtain a steep dose gradient between the lesion and the adjacent healthy cerebral parenchyma. They use minibeams (diameter less than 3 cm) of different types of radiations: protons (Kjellberg from Harvard, since 1962); gamma rays of cobalt 60 (Leksell from Stockholm, since 1968); and X-rays from a linear accelerator (Betti from Buenos-Aires, since 1982). The most commonly treated lesions are arterio-venous malformations, hypophyseal adenomas and low grade parenchymatous tumors. The stereotaxic technique is the only means by which to insure that these high dose irradiations, administered in a single session, are actually delivered to the small lesions situated in the cerebral parenchyma.

Adenoma↗
PubMed1988

Late pleuropulmonary metastases of a cerebral ependymoma.

A patient with a 12-year history of occipital ependymoma was found to have late pleuropulmonary metastases without recurrence of the primary tumor. The pleural metastases were diagnosed by histologic, ultrastructural features and finally by glial fibrillary acidic protein (GFAP) labeling positive reaction. This case is unique because of the long interval between occurrence of the initial tumor and the metastases, and because of the apparent quiescence of the cerebral lesion when the pleuropulmonary metastases were discovered.

Adult↗
PubMed1988

[Thoracic metastases of ependymoma. Apropos of a case and review of the literature].

A 27-year old woman with occipital ependymoma treated by surgery and radiotherapy for multiple recurrences developed a right lymphocytic pleural effusion. After 3 inconclusive needle biopsies of the pleura, pleurectomy was performed. Pathological examination with a specific immunohistochemical marker provided a diagnosis of pleuro-pulmonary metastases from the ependymoma. This rare case of extraneuraxial metastasis from a cerebral ependymoma is discussed in the light of published data. Its originality lies in that a positive diagnosis of pleural metastases was obtained with an immunohistochemical marker, the gliofibrillary antiprotein serum (anti-GFAP) specific of glial tissue.

Adult↗
PubMed1987

[Peroperative radiotherapy in cancer of the pancreas].

Intra-operative irradiation has been devised as a method to safely deliver higher radiation doses to the tumors while minimizing the dose to the surrounding normal tissues. Among 12 patients treated by intraoperative radiotherapy in our institution, 7 had a pancreatic carcinoma (unresected in 6 patients, and partially resected in 1). Anesthetized patients were transferred with the incision temporarily closed from the fourth floor operating theatre to the basement accelerator suite. A single dose of 15 to 20 Gy with 20 MeV electrons was delivered. Five of these patients with carcinoma of the head of the pancreas then had a biliary and a digestive bypass. After surgery, all patients received an additional 40 Gy and chemotherapy with 5-fluorouracil. There was neither post-operative mortality nor morbidity. Three patients with pre-operative pain had no pain following treatment. Five patients died after 5 to 10 months and two patients are alive with a follow-up of 4 and 9 months respectively. Because of the short follow-up and small number of patients, no conclusions concerning survival can be drawn. Nevertheless, in other experiences good palliative results have generally been obtained. Significant differences in survival time were noted in a japanese experience of unresected cases. In 16 patients with resected carcinoma a 41% survival rate at 2 years has been observed in 1 North American study. These results suggest that intra-operative irradiation is worth further trials.

Aged↗
PubMed1987

Hodgkin's disease, clinical stages IA to IIIB: combined modality therapy (3 MOPP followed by curative and prophylactic radiotherapy including the spleen). Six-year results.

From January 1980 to September 1985, 82 patients with IA to IIIB clinical stage (CS) Hodgkin's disease were treated by three MOPP chemotherapy (CT) cycles followed by extended field radiotherapy (RT) including the spleen (30-40 Gy). 2 patients died during the treatment (medullary aplasia, pulmonary edema). 6 were in failure after three MOPP cycles; they received other CT; 3 died and 3 are alive in remission (survival: 2.5 to 3.5 yr). 74 were in complete remission (CR) after completion of treatment. 4 patients relapsed (all alive after re-treatment) and 4 died in first CR (tuberculosis, hepatitis, myeloma, unknown cause). At 6 yr, actuarial survival and relapse-free survival are respectively 89.8% for the 82 patients and 93% for those in CR. These good results are due to: the administration of CT before RT, limited to three cycles; identification of failures after CT; inclusion of the spleen in RT ports in all cases; and a short lumbo-aortic port in CS I and II.

Combined Modality Therapy↗
PubMed1987

[Peroperative radiotherapy in cancer of the pancreas].

7 patients presenting with unresected (6 cases) or resected (1 case) cancer of the pancreas were treated peroperatively by radiotherapy. Tumors were treated with 15 to 20 Gy delivered by a particle accelerator. There were no post-operative complications. Three patients who were experiencing pain before radiotherapy no longer had pain after radiotherapy and this effect was maintained. Five patients died during the follow-up period after 5 to 10 months. Two patients are still alive after 4 and 9 months' follow-up. This experience with peroperative radiotherapy should be continued.

Aged↗
PubMed1986

An interim assessment of the experience of fast neutron boost in inoperable rectal carcinomas in Orléans.

Since January 1981, 58 patients with postoperative recurrences or inoperable rectal cancer have been included in a trial featuring a neutron boost after an initial series of irradiation given by the classical high energy photon procedure. This group irradiated at the Neutrontherapy Unit in Orléans was compared to a historical series of 52 patients treated by X-rays only at the Tumor Treatment Center of the Hôpital Tenon in Paris. The immediate local control rate for the neutron group was higher than that obtained by irradiation with photon alone (23/31 vs 14/50). Immediate tolerance was generally satisfactory in both groups. The two survival curves are practically identical.

Adenocarcinoma↗
PubMed1985

A prospective study of detorubicin in malignant mesothelioma.

Between January 1981 and December 1983, a prospective therapeutic trial of detorubicin (14-diethoxyacetoxy-daunorubicin [DTR]) was conducted in 40 patients with histologically proven malignant mesothelioma (MM). DTR was given intravenously at 40 mg/m2 on days 1, 2, and 3 for five 21-day cycles, then 40 mg/m2 once every 21 days. Thirty-five patients (32 with pleural MM, 3 with peritoneal MM) were eligible. The overall median survival from onset of chemotherapy was 17 months. Complete relief from chest pain was observed in 8 of 15 cases (53%). Of 21 patients with measurable disease, there were 2 complete responses (10%) and 7 partial responses (33%). Median duration of response was 30 weeks. Congestive cardiac failure developed in two patients after 1100 and 1600 mg/m2 of DTR, respectively. Hematologic toxicity was moderate. This study demonstrates that DTR is effective against MM.

Adult↗
PubMed1985

[Primary pseudo-ovarian peritoneal carcinosis. 4 cases].

Primary papillary carcinosis of the peritoneum is a rare disease seen in elderly women in whom no digestive or ovarian carcinoma could be detected. Its histological structure is identical with that of papillary carcinoma of the ovary. The 4 cases reported here were treated as advanced ovarian carcinomas, with multiple chemotherapy including doxorubicin and cis-platinum. Three patients were re-operated upon after 6 courses. Complete remission was obtained in all 4 cases, but the patients relapsed under maintenance therapy. The diagnosis must be suspected in elderly women presenting with unexplained carcinosis. This is particularly important since effective treatments can now be proposed, as for advanced ovarian carcinomas.

Adenocarcinoma, Papillary↗